Lowest-Rated StocksLowest-RatedMost-Downgraded StocksMost-DowngradedNASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $8.73 +0.28 (+3.31%) Closing price 04:00 PM EasternExtended Trading$8.56 -0.17 (-1.95%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RxSight Stock (NASDAQ:RXST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RxSight alerts:Sign Up Key Stats Today's Range$8.20▼$8.8550-Day Range$6.65▼$14.2752-Week Range$6.32▼$58.23Volume1.02 million shsAverage Volume1.04 million shsMarket Capitalization$357.23 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingReduce Company Overview RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Read More RxSight Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreRXST MarketRank™: RxSight scored higher than 34% of companies evaluated by MarketBeat, and ranked 772nd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingRxSight has received a consensus rating of Reduce. The company's average rating score is 1.91, and is based on 1 buy rating, 8 hold ratings, and 2 sell ratings.Amount of Analyst CoverageRxSight has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about RxSight's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -10.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -10.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.40% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in RxSight has recently increased by 25.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.40% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in RxSight has recently increased by 25.60%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.00 News SentimentRxSight has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 37 news articles for RxSight this week, compared to 11 articles on an average week.MarketBeat Follows2 people have added RxSight to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.57% of the stock of RxSight is held by insiders.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Stock News HeadlinesLost Money on RxSight, Inc.(RXST)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm3 hours ago | globenewswire.comDeadline Alert: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit4 hours ago | globenewswire.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 21 at 2:00 AM | Weiss Ratings (Ad)SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSightAugust 21 at 11:25 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXSTAugust 21 at 10:36 AM | globenewswire.comClass Action Filed Against RxSight, Inc. (RXST) - September 22, 2025 Deadline to Join - Contact The Gross Law FirmAugust 21 at 8:45 AM | prnewswire.comRXST DEADLINE NOTICE: RxSight, Inc. Investors are Notified of the September 22 Class Action Deadline -- Contact BFA Law if You Suffered Losses (NASDAQ:RXST)August 21 at 8:18 AM | globenewswire.comShareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22ndAugust 21 at 7:05 AM | prnewswire.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $34.38 on January 1st, 2025. Since then, RXST stock has decreased by 74.5% and is now trading at $8.76. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.04. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. Read the conference call transcript. When did RxSight IPO? RxSight (RXST) raised $125 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share. Who are RxSight's major shareholders? Top institutional shareholders of RxSight include Artisan Partners Limited Partnership (5.50%), Brown Capital Management LLC (2.74%), BNP Paribas Financial Markets (1.18%) and New York State Common Retirement Fund (1.14%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Ilya Goldshleger, Julie Andrews, Bakker Juliet Tammenoms, Robert Keith Warner, Tamara Fountain, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RxSight own? Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON). Company Calendar Last Earnings8/07/2025Today8/21/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Price Target for RxSight$10.00 High Price Target$17.00 Low Price Target$8.00 Potential Upside/Downside+14.5%Consensus RatingReduce Rating Score (0-4)1.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.45 million Net Margins-21.93% Pretax Margin-21.88% Return on Equity-11.56% Return on Assets-10.31% Debt Debt-to-Equity RatioN/A Current Ratio13.93 Quick Ratio12.70 Sales & Book Value Annual Sales$139.93 million Price / Sales2.55 Cash FlowN/A Price / Cash FlowN/A Book Value$6.79 per share Price / Book1.29Miscellaneous Outstanding Shares40,920,000Free Float37,000,000Market Cap$357.23 million OptionableOptionable Beta1.16 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:RXST) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.